Dyne Therapeutics, Inc. (NASDAQ:DYN) Position Lifted by Trexquant Investment LP

Trexquant Investment LP raised its holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 95.6% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 125,378 shares of the company's stock after purchasing an additional 61,288 shares during the period. Trexquant Investment LP owned 0.12% of Dyne Therapeutics worth $2,954,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of DYN. Quantbot Technologies LP purchased a new stake in Dyne Therapeutics during the 3rd quarter worth about $34,000. Point72 DIFC Ltd acquired a new stake in shares of Dyne Therapeutics during the 3rd quarter worth about $36,000. KBC Group NV boosted its stake in shares of Dyne Therapeutics by 45.3% during the 4th quarter. KBC Group NV now owns 3,135 shares of the company's stock worth $74,000 after purchasing an additional 978 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new stake in shares of Dyne Therapeutics during the fourth quarter worth about $257,000. Finally, Magnetar Financial LLC acquired a new position in shares of Dyne Therapeutics in the fourth quarter valued at approximately $263,000. 96.68% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, insider Oxana Beskrovnaya sold 2,598 shares of the stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $13.95, for a total value of $36,242.10. Following the completion of the transaction, the insider now owns 199,087 shares of the company's stock, valued at approximately $2,777,263.65. This represents a 1.29 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Insiders have sold 6,237 shares of company stock valued at $77,760 in the last quarter. Company insiders own 20.77% of the company's stock.

Wall Street Analyst Weigh In

DYN has been the topic of a number of analyst reports. Baird R W upgraded shares of Dyne Therapeutics to a "strong-buy" rating in a research report on Thursday, December 12th. Chardan Capital restated a "buy" rating and set a $50.00 price objective on shares of Dyne Therapeutics in a report on Monday, March 17th. Guggenheim reaffirmed a "buy" rating on shares of Dyne Therapeutics in a research report on Friday, January 24th. Scotiabank assumed coverage on Dyne Therapeutics in a research report on Friday, March 7th. They set a "sector outperform" rating and a $50.00 target price on the stock. Finally, BMO Capital Markets started coverage on Dyne Therapeutics in a report on Wednesday, March 12th. They issued an "outperform" rating and a $50.00 price target for the company. One analyst has rated the stock with a sell rating, one has issued a hold rating, twelve have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Dyne Therapeutics currently has an average rating of "Moderate Buy" and an average target price of $47.46.

Dyne Therapeutics Stock Performance

Shares of NASDAQ:DYN traded up $0.06 during mid-day trading on Friday, hitting $7.04. 1,349,052 shares of the company traded hands, compared to its average volume of 1,469,918. The firm's 50 day simple moving average is $11.86 and its 200 day simple moving average is $21.34. The firm has a market cap of $796.37 million, a P/E ratio of -1.98 and a beta of 1.21. Dyne Therapeutics, Inc. has a 52-week low of $6.36 and a 52-week high of $47.45.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last posted its quarterly earnings data on Tuesday, March 4th. The company reported ($0.88) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.92) by $0.04. Equities research analysts expect that Dyne Therapeutics, Inc. will post -3.44 EPS for the current fiscal year.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.